Lipomatous medulloblastoma is not a separate entity but apparently distinct variant of medulloblastoma. Since the first case report in 1978 by Bechtel et al. [1] , few cases have been published. We report an additional case of a 52-year-old right-handed man presented to the emergency department with evaluation of progressive severe intracranial hypertension and ataxia. His past medical history was unremarkable. His physical examination showed cerebellar syndromes. He underwent magnetic resonance imaging (MRI) which revealed a unique mass in the posterior fossa, lying within a cerebellar hemisphere. The patient underwent a suboccipital craniotomy for with a complete resection and samples were sent for histologic examination, showing closely packed, and round to oval cells. The nuclei had an irregular shape with clumps of heterochromatin. Lipid accumulation was a prominent feature of neoplastic cells. Postoperatively the patient did not receive fractionated radiotherapy. He is alive without deficit and with no evidence of recurrence on neuroimaging.
Introduction
Lipomatous medulloblastoma is not an entity but apparently distinct variant of medulloblastoma. The first case report was 1978 by Bechtel et al. [1] . It was first included in the 2000 World Health Organisation (WHO) 3rd edition of Central Nervous System (CNS) tumors' classification as a separate grade I entity labelled as cerebellar liponeurocytoma, but the histo-pathological origin of this tumor is How to cite this paper: Berete, I., Bah, A.B., Diawara, S., Nawal, H., Benzagmout, M., Chakour, K. and Chaoui, M. [2] . We report an additional case in an adult who presented with a posterior fossa tumor. 
Case Report

Discussion
Medulloblastoma is the most common solid malignancy seen in children. [9] . Although WHO criteria have labeled this variant as a "cerebellar liponeurocytoma", the histopathological origin of this tumor is still controversial.
Therefore, because of the glial versus neuronal origin conflict with this tumor, we have decided to label it as a lipomatous medulloblastoma. Most reported cases have occurred in middle-aged adults (median age, 50; range, 30 -66). Gender predilection appears to be evenly distributed (Sex-ratio 2F/3H) [5] . All but one tumor arose in the cerebellum, with the exception being a supratentorial tumor located in periventricular white matter [8] . It has been suggested that this tumor variant may be more likely to appear hyperintense on T1-weighted MRI [4] . In our patient it was not the case, and this imaging characteristic should be considered unreliable. The pathologic findings are typical for medulloblastoma, positive immunohistochemical staining for neuron-specific enolase (NSE) and glial fibrillary acidic protein (GFAP) [7] . The only differentiating factor was the abundancy of intracytoplasmic lipid accumulation. Because of the presence of adipocytes, additional terms that have been proposed for these tumors including neurolipocytoma and medullocytoma [10] . The lipomatous variant of medulloblastoma carries a very different prognosis than the classical medulloblastoma [6] . In the absence of postoperative complications, high long-term survival ap-Open Journal of Modern Neurosurgery pears to be the rule rather than the exception for these patients. Only 6 cases of postoperative radiotherapy were reported [2] [3] . Our study is concordant with the literature in their adult presentation and posterior fossa predilection. The fact that our patient has no evidence of disease recurrence at follow-up after complete resection confirms the uniquely benign prognosis of this distinct medulloblastoma variant.
Conclusion
The present study reported a case of lipomatous medulloblastoma that was successfully treated by total resection. A review of the literature showed that distinct variant of medulloblastoma is rare, may locate supratentorially or infratentorially and appear to occur in adults. The optimal treatment strategy appears to be a total resection and close follow-up, with a uniquely favorable prognosis. However, due to the rarity of the tumor and limited data available, long-term follow-up is required.
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